Individual glioblastoma cells harbor both proliferative and invasive capabilities during tumor progression
- PMID: 37335907
- PMCID: PMC10708941
- DOI: 10.1093/neuonc/noad109
Individual glioblastoma cells harbor both proliferative and invasive capabilities during tumor progression
Abstract
Background: Glioblastomas are characterized by aggressive and infiltrative growth, and by striking heterogeneity. The aim of this study was to investigate whether tumor cell proliferation and invasion are interrelated, or rather distinct features of different cell populations.
Methods: Tumor cell invasion and proliferation were longitudinally determined in real-time using 3D in vivo 2-photon laser scanning microscopy over weeks. Glioblastoma cells expressed fluorescent markers that permitted the identification of their mitotic history or their cycling versus non-cycling cell state.
Results: Live reporter systems were established that allowed us to dynamically determine the invasive behavior, and previous or actual proliferation of distinct glioblastoma cells, in different tumor regions and disease stages over time. Particularly invasive tumor cells that migrated far away from the main tumor mass, when followed over weeks, had a history of marked proliferation and maintained their proliferative capacity during brain colonization. Infiltrating cells showed fewer connections to the multicellular tumor cell network, a typical feature of gliomas. Once tumor cells colonized a new brain region, their phenotype progressively transitioned into tumor microtube-rich, interconnected, slower-cycling glioblastoma cells. Analysis of resected human glioblastomas confirmed a higher proliferative potential of tumor cells from the invasion zone.
Conclusions: The detection of glioblastoma cells that harbor both particularly high proliferative and invasive capabilities during brain tumor progression provides valuable insights into the interrelatedness of proliferation and migration-2 central traits of malignancy in glioma. This contributes to our understanding of how the brain is efficiently colonized in this disease.
Keywords: cancer neuroscience; glioblastoma; migration; proliferation; tumor microtubes (TMs).
© The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Conflict of interest statement
F.W., E.J., M.O. and W.W. report the patent (WO2017020982A1) “‘Agents for use in the treatment of glioma.’” F.W. is co-founder of DC Europa Ltd (a company trading under the name Divide and Conquer) that is developing new medicines for the treatment of glioma. Divide and Conquer also provides research funding to F.W.’s lab under a research collaboration agreement.
Figures






Comment in
-
Glioblastoma cell invasion: Go? Grow? Yes.Neuro Oncol. 2023 Dec 8;25(12):2163-2164. doi: 10.1093/neuonc/noad178. Neuro Oncol. 2023. PMID: 37739005 Free PMC article. No abstract available.
Similar articles
-
Tweety-Homolog 1 Drives Brain Colonization of Gliomas.J Neurosci. 2017 Jul 19;37(29):6837-6850. doi: 10.1523/JNEUROSCI.3532-16.2017. Epub 2017 Jun 12. J Neurosci. 2017. PMID: 28607172 Free PMC article.
-
Time-lapse phenotyping of invasive glioma cells ex vivo reveals subtype-specific movement patterns guided by tumor core signaling.Exp Cell Res. 2016 Dec 10;349(2):199-213. doi: 10.1016/j.yexcr.2016.08.001. Epub 2016 Aug 8. Exp Cell Res. 2016. PMID: 27515001
-
Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion.Mol Cancer. 2012 May 14;11:32. doi: 10.1186/1476-4598-11-32. Mol Cancer. 2012. PMID: 22583806 Free PMC article.
-
Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.Drug Resist Updat. 2015 Mar;19:1-12. doi: 10.1016/j.drup.2015.02.002. Epub 2015 Mar 6. Drug Resist Updat. 2015. PMID: 25791797 Review.
-
Glioblastoma quo vadis: Will migration and invasiveness reemerge as therapeutic targets?Cancer Treat Rev. 2018 Jul;68:145-154. doi: 10.1016/j.ctrv.2018.06.017. Epub 2018 Jun 26. Cancer Treat Rev. 2018. PMID: 30032756 Review.
Cited by
-
Disrupting glioblastoma networks with tumor treating fields (TTFields) in in vitro models.J Neurooncol. 2024 Oct;170(1):139-151. doi: 10.1007/s11060-024-04786-0. Epub 2024 Aug 1. J Neurooncol. 2024. PMID: 39088157 Free PMC article.
-
TBX15 facilitates malignant progression of glioma by transcriptional activation of TXDNC5.iScience. 2024 Jan 18;27(2):108950. doi: 10.1016/j.isci.2024.108950. eCollection 2024 Feb 16. iScience. 2024. PMID: 38327797 Free PMC article.
-
The Alcatraz-Strategy: a roadmap to break the connectivity barrier in malignant brain tumours.Mol Oncol. 2024 Dec;18(12):2890-2905. doi: 10.1002/1878-0261.13642. Epub 2024 Apr 3. Mol Oncol. 2024. PMID: 38567664 Free PMC article. Review.
-
Hypoxia drives shared and distinct transcriptomic changes in two invasive glioma stem cell lines.Sci Rep. 2024 Mar 27;14(1):7246. doi: 10.1038/s41598-024-56102-5. Sci Rep. 2024. PMID: 38538643 Free PMC article.
-
Multicellular Model of Temozolomide Resistance in Glioblastoma Reveals Phenotypic Shifts in Drug Response and Migratory Potential.bioRxiv [Preprint]. 2025 Jul 11:2025.07.08.663674. doi: 10.1101/2025.07.08.663674. bioRxiv. 2025. PMID: 40672268 Free PMC article. Preprint.
References
-
- Venkataramani V, Yang Y, Schubert MC, et al. . Glioblastoma hijacks neuronal mechanisms for brain invasion. Cell. 2022;185(16):2899–2917. - PubMed
-
- Giese A, Bjerkvig R, Berens ME, Westphal M.. Cost of migration: Invasion of malignant gliomas and implications for treatment. J Clin Oncol. 2003;21(8):1624–1636. - PubMed
-
- Sahm F, Capper D, Jeibmann A, et al. . Addressing diffuse glioma as a systemic brain disease with single-cell analysis. Arch Neurol. 2012;69(4):523–526. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical